Rezolute (RZLT) announced that enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital HI. “The completion of enrollment in the sunRIZE study is a significant milestone for Rezolute and those affected by congenital hyperinsulinism,” said Brian Roberts, M.D., Chief Medical Officer at Rezolute. “This achievement brings us one step closer to potentially offering a new therapeutic option in a space where few exist. We are deeply grateful to the patients, families, and investigators who are helping to advance care in an area that has long been underserved, and we look forward to announcing topline data later this year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute, Inc. (RZLT) Q3 Earnings Cheat Sheet
- Rezolute’s Financial Stability and Clinical Progress Drive Buy Rating Amid Promising Phase 3 Trials
- Rezolute’s Promising Market Position and Clinical Advancements Drive Buy Rating
- Rezolute’s Ersodetug Shows Promise in Phase 3 Trials for CHI, Reinforcing Buy Rating and $12 Price Target
- Optimistic Buy Rating for Rezolute Driven by Promising Ersodetug Developments and Strong Financial Position